Cardiometabolic health in offspring of women with PCOS compared to healthy controls: a systematic review and individual participant data meta-analysis by Gunning, M.N. (Marlise N.) et al.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com
Human Reproduction Update, Vol.26, No.1, pp. 104–118, 2020
Advance Access Publication on December 23, 2019 doi:10.1093/humupd/dmz036
Cardiometabolic health in offspring of
women with PCOS compared to
healthy controls: a systematic review
and individual participant data
meta-analysis
Marlise N.Gunning 1,*, Teresa Sir Petermann2,3, Nicolas Crisosto2,3,
Bas B. van Rijn4,5,Marlieke A. de Wilde1, Jacob P.Christ1,
C.S.P.M.Uiterwaal6,Wilco de Jager7,Marinus J.C. Eijkemans1,6,
Allen R. Kunselman8, Richard S. Legro8, and Bart C.J.M. Fauser1
1Department of Reproductive Medicine, Obstetrics and Gynecology, University Medical Center Utrecht, Utrecht University, Utrecht, The
Netherlands 2Endocrinology and Metabolism, University of Chile, Santiago, Chile 3Unit of Endocrinology, Clinica Las Condes, Santiago,
Chile 4Department of Obstetrics and Gynecology, Erasmus Medical Center, University Medical Center Rotterdam, The Netherlands
5Department of Obstetrics, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht University, The Netherlands 6Julius
Centre for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands 7Department of Pediatric
Immunology, Centre for Molecular and Cellular Intervention, University Medical Centre Utrecht, Utrecht University, Utrecht, The
Netherlands 8Department of Obstetrics and Gynecology, Penn State University College of Medicine, Hershey, PA, USA
*Correspondence address. Department of Reproductive Medicine, Obstetrics and Gynecology, University Medical Center Utrecht, Utrecht
University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Tel: +31-8-87-55-30-68; Fax: +31-8-87-55-55-07; E-mail:
m.n.gunning@umcutrecht.nl https://orcid.org/0000-0002-6283-2983
Submitted on February 19, 2019; resubmitted on July 28, 2019; editorial decision on August 8, 2019
TABLE OF CONTENTS
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
• Introduction
• Methods
Search strategy
Study selection
Data extraction
Statistical analyses
• Results
Search strategy and data selection
Meta-analysis results
• Discussion
• Conclusion
BACKGROUND:Women diagnosed with polycystic ovary syndrome (PCOS) suffer from an unfavorable cardiometabolic risk profile, which
is already established by child-bearing age.
OBJECTIVE AND RATIONALE: The aim of this systematic review along with an individual participant data meta-analysis is to evaluate
whether cardiometabolic features in the offspring (females and males aged 1–18 years) of women with PCOS (OPCOS) are less favorable
compared to the offspring of healthy controls.
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SEARCH METHODS: PubMed, Embase and gray literature databases were searched by three authors independently (M.N.G., M.A.W and
J.C.) (last updated on 1 February 2018). Relevant key terms such as ‘offspring’ and ‘PCOS’ were combined. Outcomes were age-specific
standardized scores of various cardiometabolic parameters: BMI, blood pressure, glucose, insulin, lipid profile and the sum scores of various
cardiometabolic features (metabolic sum score). Linear mixed models were used for analyses with standardized beta (β) as outcome.
OUTCOMES: Nine relevant observational studies could be identified, which jointly included 1367 children: OPCOS and controls, originating
from the Netherlands, Chile and the USA. After excluding neonates, duplicate records and follow-up screenings, a total of 885 subjects
remained. In adjusted analyses, we observed that OPCOS (n=298) exhibited increased plasma levels of fasting insulin (β =0.21(95%CI: 0.01–
0.41), P=0.05), insulin-resistance (β =0.21(95%CI: 0.01–0.42), P=0.04), triglycerides (β =0.19(95%CI: 0.02–0.36), P=0.03) and high-density
lipoprotein (HDL)-cholesterol concentrations (β =0.31(95%CI: 0.08–0.54), P< 0.01), but a reduced birthweight (β =−116(95%CI: −195 to
38), P< 0.01) compared to controls (n=587). After correction for multiple testing, however, differences in insulin and triglycerides lost their
statistical significance. Interaction tests for sex revealed differences between males and females when comparing OPCOS versus controls. A
higher 2-hour fasting insulin was observed among female OPCOS versus female controls (estimated difference for females (β f ) = 0.45(95%CI:
0.07 to 0.83)) compared to the estimated difference between males ((βm) =−0.20(95%CI: −0.58 to 0.19)), with interaction-test: P=0.03.
Low-density lipoprotein–cholesterol differences in OPCOS versus controls were lower among females (β f =−0.39(95%CI: −0.62 to
0.16)), but comparable between male OPCOS and male controls (βm =0.27(95%CI: −0.03 to 0.57)), with interaction-test: P< 0.01. Total
cholesterol differences in OPCOS versus controls were also lower in females compared to the difference in male OPCOS and male controls
(β f =−0.31(95%CI: −0.57 to 0.06), βm =0.28(95%CI: −0.01 to 0.56), interaction-test: P=0.01). The difference in HDL-cholesterol among
female OPCOS versus controls (β f =0.53(95%CI: 0.18–0.88)) was larger compared to the estimated mean difference among OPCOS males
and themale controls (βm =0.13(95%CI:−0.05−0.31), interaction-test: P< 0.01). Interaction test in metabolic sum score revealed a significant
difference between females (OPCOS versus controls) and males (OPCOS versus controls); however, sub analyses performed in both sexes
separately did not reveal a difference among females (OPCOS versus controls: β f =−0.14(95%CI: −1.05 to 0.77)) or males (OPCOS versus
controls: βm =0.85(95%CI: −0.10 to 1.79)), with P-value < 0.01.
WIDER IMPLICATIONS:Weobserved subtle signs of altered cardiometabolic health in OPCOS. Therefore, the unfavorable cardiovascular
profile of women with PCOS at childbearing age may—next to a genetic predisposition—influence the health of their offspring. Sensitivity
analyses revealed that these differences were predominantly observed among female offspring aged between 1 and 18 years. Moreover, studies
with minimal risk of bias should elucidate the influence of a PCOS diagnosis in mothers on both sexes during fetal development and subsequently
during childhood.
Key words: PCOS / preconception / periconception / offspring / children / cardiovascular health / metabolic health / cardiometabolic
health / sex differences
Introduction
Polycystic ovary syndrome (PCOS) represents a heterogeneous con-
dition often including ovulatory dysfunction, hyperandrogenemia and
characteristic alterations in ovarian morphology, and is present in 6–
15% of all women of reproductive age (Fauser et al., 2012; Williams
et al., 2016). Obesity, insulin resistance, dyslipidemia and type 2 dia-
betes mellitus are all features frequently associated with PCOS (Moran
et al., 2010; Fauser et al., 2012). In addition, PCOS often runs in families
(Legro et al., 1998; Kahsar-Miller et al., 2001), suggesting a genetic
component (Carey et al., 1993; Urbanek et al., 1999; Day et al., 2018).
PCOS is often diagnosed in women who wish to conceive. Recent
research revealed that even during singleton pregnancies, women with
PCOS present with increased pregnancy complication rates, such as
gestational diabetes mellitus, pregnancy induced hypertension and pre-
eclampsia (Boomsma et al., 2006). Moreover, neonates born from
womenwith PCOS present with increased neonatal complication rates,
especially resulting from preterm birth (Boomsma et al., 2006; Palomba
et al., 2015; Christ et al., 2019).
The Barker hypothesis implies that the health and development of
children is directly affected by the intrauterine environment (Barker
et al., 1989; Kermack et al., 2015; Paauw et al., 2017). An association
between maternal health and offspring health has been convincingly
demonstrated in the general population (Reynolds et al., 2007; Yu
et al., 2013; Gaillard et al., 2014). The maternal influence is hypoth-
esized to be exerted via fetal programming, which occurs in utero
during critical development stages in early embryonic and fetal life
(Kwon and Kim, 2017). Fetal programming may affect male and female
fetuses differently in the intrauterine environment. Animal studies, for
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example, report on higher offspring blood pressure in males compared
to females in response to maternal pharmacological glucocorticoid
administration during gestation (Dodic et al., 1998, 2002). However,
in human studies concerning adiposity in offspring, female offspring
appear to be more sensitive to increased maternal glucose levels
(Regnault et al., 2013).
Currently, limited information is available regarding health of the
offspring of women with PCOS (OPCOS). The sample size of the
studies in OPCOS is rather small and the possibility to adjust for
confounding factors is therefore limited. Themajority of human studies
in PCOS predominantly report on female offspring. Moreover, existing
literature concerning metabolic outcomes in OPCOS is inconsistent.
For example, the increased insulin concentrations found in the Amer-
ican and Chilean OPCOS (Sir-Petermann et al., 2007; Kent et al.,
2008; Legro et al., 2017) were not observed in Dutch children from
mothers with PCOS (Wilde et al., 2018). Cardiometabolic derailments
in childhood are often subtle, but may still have distinct implications
for cardiovascular health in adulthood (Daniels, 2001; Baker et al.,
2007; Singh et al., 2008). In two studies including both female and male
offspring, no sex differences were observed in anthropometrics, lipid
profile or glucose and insulin concentrations in serum (Kent et al., 2008;
Wilde et al., 2018).
Therefore, the primary purpose of the current systematic review
and individual participant data (IPD) meta-analysis was to compare
cardiometabolic health in the children of women previously diagnosed
with PCOS to healthy controls. Second, we aim to explore whether
any differences in metabolic and other factors in female and male
OPCOS exist. An IPD meta-analysis was conducted to increase the
power to detect potential differences. We hypothesize that OPCOS
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
upd/article-abstract/26/1/104/5684966 by Erasm
us U
niversity R
otterdam
 user on 15 January 2020
106 Gunning et al.
exhibit worse increased insulin concentrations compared to healthy
controls.
Methods
We conducted our systematic review according to PRISMA guidelines
(Moher et al., 2009). A systematic search in the PubMed and EMBASE
was performed on 1 June 2016 and last updated on 1 February
2018. Relevant key terms such as ‘offspring’ and ‘polycystic ovarian
syndrome’ and serum hormones such as ‘glucose’ and ‘insulin’ were
combined in a search syntax with the use of database specific subject
headings (e.g. MeSH-terms in PubMed). There was no methodological
search term (e.g. ‘cohort’ or ‘case-control’) added to the search syntax,
because we expected little added value in the completeness of the
articles retrieved by our search (Supplementary Table S1). We also
conducted an online gray literature search. Duplicates were removed
electronically and manually by using Mendeley software. The full search
terms are listed in the Supplementary Table SI. The study protocol
is registered at PROSPERO with number: CRD42019117798 (http://
www.crd.york.ac.uk/PROSPERO/).
Study selection
We selected studies on children of women with PCOS. PCOS diag-
nosis must be performed by a physician in a standardized fashion in all
mothers of the included children. We included studies with children
between 1 and 18 years of age, regardless of sex. Studies reporting
on children in the neonatal period were excluded because they mainly
focused on pregnancy and perinatal outcomes (Anderson et al., 2010).
We intended to focus on features potentially relevant for prediction of
long-term health outcomes: BMI, blood pressure, fasting and post-load
(after oral glucose administration) levels of serum glucose and insulin,
and lipid profile. Only human studies with original data were eligible for
inclusion. All English, Dutch, German, French and Spanish publications
were included. Commentaries, opinion papers, case reports, small case
series (n< 10) and systematic reviews were not eligible for inclusion.
We used similar criteria for title and abstract screening as for the full
text screening. Authors who independently performed the screening
(M.N.G., M.A.W. and J.P.C.) endorsed the final selection of articles.
A fourth author (B.C.J.M.F.) was available when consensus on final
article selection was not achieved. The final step in study selection
was performing a thorough check of the reference lists of all relevant
articles, regardless of design, in the search (cross reference checking)
(Fig. 1).
Risk of bias assessment
Internal validity of the individual studies was assessed using the New-
castle Ottawa Quality Assessment Scale (NOS). The NOS is recom-
mended for observational studies, whichwas the expected study design
for our research question (Wells et al., 2014). The three main cate-
gories of theNOS are: selection of patients and controls, comparability
of patients and controls and exposure of both groups. The NOS has
the possibility to add study specific elements to its criteria. Considering
our hypothesis, we chose to specifically assess the adjustment for age,
sex and socio-economic status. Each study separately received a risk
of bias level: high (1–3 stars), medium (4–6 stars) or low (7–9 stars)
(Supplementary Table SII).
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Data collection
Authors of studies eligible for inclusion in our IPD meta-analysis
were invited to join our study and share their data. As previously
published, the research groups received approval for the individual
studies from the local medical ethics committee. Requested data com-
prised continuous data on maternal characteristics, birthweight of their
offspring and data on the cardiometabolic status of the offspring. An
exception was dichotomous data on sex, gestation (multiple/singleton)
and presence of siblings in the dataset. Received data were uniformly
coded and harmonized in one dataset (Figs 2 and 3). We converted
all serum concentrations into similar units of measure. The Dutch data
on glucose and lipid profiles were converted from millimole per liter
(mmol/L) to milligram per deciliter (mg/dL) (Haney et al., 2007). No
further harmonization issues had to be encountered.
The outcomes were parameters of the cardiometabolic profile of
offspring: age- and sex-corrected BMI and systolic blood pressure
(SBP), and age-corrected fasting and post-load insulin and glucose
concentrations, homeostatic model assessment for insulin resis-
tance (HOMA-IR), total-cholesterol, triglycerides, low/high-density
lipoprotein-cholesterol (LDL/HDL-c) concentrations and composites
of the aforementioned offspring parameters: themetabolic sum scores.
We calculated HOMA-IR levels if not yet present in the received
datasets, which is a measure for insulin resistance (HOMA-IR= [fasting
insulin (μU/ml)∗fasting glucose (mmol/liter)]/405) (Matthews et al.,
1985). Due to the lack of consensus on how to define the
metabolic syndrome in children, we calculated two different metabolic
sum scores, a summation of multiple standardized scores (SDS)
(Eisenmann, 2008). First, we calculated metabolic sum score-1, a
composite of BMI, SBP, fasting insulin, triglycerides and HDL-c. Second,
we calculated metabolic sum score-2, a composite of waist-to-height
ratio, SBP, glucose, triglycerides and HDL-c. Metabolic sum score-2
was previously used in a large Dutch cohort study (Oostvogels et al.,
2014).
Statistical analysis
Continuous normally distributed data were summarized with a mean
and SD, and if non-normally distributes a median and interquartile
range (IQR) were used. Categorical variables were summarized by
number and percentage. We used the square root of fasting and post-
load insulin concentrations and HOMA-IR, since these variables were
non-normally distributed.
For missing baseline characteristics, multiple imputations (n=5)
following the predictive mean matching principal was used. We
calculated age-specific SDS based on the control population for all
metabolic parameters. We used the World Health Organization
(WHO) reference standards of 2007 to calculate the BMI SDS for
each child using a WHO tool: WHO Anthro version 3.2.2, January
2011 (WHO, 2006, 2011). The BMI SDS accounts for the age and
sex of the child and is universally applicable. We also calculated
age- and sex-dependent SBP percentiles according to The Fourth
Report on the Diagnosis, Evaluation, and Treatment of High Blood
Pressure in Children and Adolescents (National Institutes of Health,
2004). Percentiles were transformed to SDS, which were used for
analyses.
Conversion of metabolic markers, as described previously, took
place before pooling all data (Haney et al., 2007).
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Figure 1 Flowchart of the search,according to PRISMA guidelines.∗ = all data in this step were available obtained and analyzed, n=number.
All numbers (n) mentioned in the exclusion criteria were extracted in the ‘screening on full-text’ step (Figure adjusted from the PRISMA group
(Moher 2009).
Heterogeneity among studies was assessed by constructing Forest
plots and performing a Chi2-test. We also evaluated potential publi-
cation bias by constructing Funnel plots. For both plots, we used the
metabolic sum score-1 (composite SDS of: BMI, SBP, fasting insulin,
triglycerides and HDL-c) of the first visits of all children and the
total number of visits of the children separately. The software utilized
was Review Manager, version 5 (Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014).
To answer our research question on cardiometabolic outcomes in
OPCOS versus controls, we used a one-step approach and constructed
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a linear mixed model with a random effect for the country or research
group the children originated from. By correcting for country of origin,
we take international differences, such as anthropometric and assay
differences, into account.
In the first analyses, we analyzed differences between OPCOS and
controls, regardless of sex, in a basic (models 1, 3, 5 and 7) and an
adjusted model (models 2, 4, 6 and 8).
For birthweight, we adjusted in a basic model only for gestational
age and the country (USA, Chile or The Netherlands) from which the
children originated (model 1). In the adjusted model, we additionally
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Figure 2 Flowchart of the study: from systematic search results to IPD dataset.This flowchart represents the four steps (four columns’
from left to right), which were undertaken to collect our final data for the IPD meta-analysis. Column (1) Participants (n) per study. Our screening
resulted in nine publications from three research groups with (n) participants per article (cases and controls together). Column (2) Received data.
Each research group shared one file with all offspring of women with PCOS (OPCOS) and all healthy controls (n), which showed that some subjects
participated in more than one publication. Column (3) Extraction <1 yr (year) and duplicates. In the third step, we excluded all children below 1 year
old and all duplicate children (children who were screened multiple times). Column (4) IPD analysis n=885. In the fourth step, a dataset remained with
885 unique children aged 1–18 years (OPCOS and controls), on which we conducted our IPD meta-analyses.
corrected birthweight for sex, parity, multiple gestation and presence
of siblings in this study (model 2).
In two variables, we calculated SDS using external reference pop-
ulations: WHO-based BMI SDS and the Centers for disease control
and prevention (CDC)-based SBP SDS. In the WHO-based BMI SDS,
the age and sex of the child are already taken into account and in
the basic model and we additionally corrected for the country from
which children originated (model 3). In the adjusted model, we also
adjusted for parity, multiple gestation and presence of siblings in this
study (model 4). In the CDC-based SBP SDS, sex, height and age
were already taken into account and we additionally adjusted for the
country from which children originated (model 5). In the adjusted
model, we added similar factors as for the adjusted model with BMI
SDS, with addition of the weight of the offspring (model 6). For all
other outcomes, in the basic model, we adjusted for age of the child
and the country from which the children originated (model 7). In the
adjusted model, we additionally corrected for sex of the child, parity
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
of the mother, multiple gestation and whether children had any siblings
in the IPD meta-analysis included (model 8).
Second, we added interaction terms to the additionally adjusted
mixed models (models 2, 4, 6 and 8) to evaluate whether sex was
an effect modifier in the association between the exposure variable
(a mother with or without PCOS diagnosis) and the dependent vari-
ables (the cardiometabolic outcomes). The P-values presented are the
results of the interaction test.We provided estimatedmean differences
with a 95% CI of OPCOS versus controls, and of the male and female
children separately, without P-values. All data were analyzed using SPSS
Statistics, version 25.0 (IBM SPSS Inc., Chicago, IL, USA). Owing to
the number of statistical tests we performed, a Bonferroni correction
for multiple testing (Chen et al., 2017) was applied. Three independent
cardiometabolic outcomes were tested: anthropometrics, insulin resis-
tance and lipid profile: outcomes were divided in these three clusters.
Therefore, the significance level P=0.05 was divided by three, which
provides a significance level corrected for multiple testing: P=0.017.
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Figure 3 Parameters measured per age category in all included centers. Total number of included children on their first visit is 885: for
two children their age and sex is missing. (n) = number of children in which the parameter is available.
Results
Search results
The systematic search identified a total of 1931 articles, of which
nine articles were selected for internal validity assessment (Fig. 1,
Supplementary Table SIII). Risk of bias assessment using the NOS
revealed six articles with a medium risk of bias and three articles with
low risk of bias (Table I).
Baseline characteristics
A total of 1367 children participated in the identified studies eligi-
ble for this IPD meta-analysis. Multiple children participated several
times during their childhood. However, we chose to use only the
first visit of all children to avoid any possible inclusion bias, i.e. an
over presentation of children with an unfavorable measurement out-
comes. Therefore, only 885 cardiovascular screenings of unique chil-
dren OPCOS=298 (female n=196, male n=102), controls n=587
(female: n=354,male: n=233)were used for the currentmixedmodel
analysis (Fig. 2).
Mean age of the OPCOS group was 8.1 years old (SD 3.7) and of
the healthy controls 7.9 years old (SD 3.7). Mean BMI was 18.8 kg/m2
(SD 4.5) in OPCOS and for the control group 18.1 kg/m2 (SD 3.8).
Mean age and BMI among mothers with PCOS was 35.7 years old (SD
6.0) and 32.4 kg/m2 (SD 8.6) and among the controls 38.1 years old
(SD 5.3) and 24.8 kg/m2 (SD 4.2), respectively. The Tanner stages
were reported by the American research group: (Kent et al., 2008)
and the Chilean research group, presented in Table II (Sir-Petermann
et al., 2009). The Chi2-tests for heterogeneity of our study population
was not significant (P=0.42) and accompanied by a non-significant
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effect on the metabolic sum score-1 status between OPCOS and
healthy controls (P=0.55). The Funnel plot reported no clear sign of
publication bias (Supplementary Figs SI and SII).
Outcomes in all children
The basic model revealed a lower birth weight in OPCOS versus
controls (β =−129 (95%CI:−208—51), P< 0.01). Furthermore,
a higher fasting insulin (β =0.21(95%CI:0.03–0.40), P=0.03) and
2 hour post-load insulin (β =0.27(0.01–0.53), P=0.04), HOMA-IR
(β =0.23(0.03–0.44), P=0.02), triglycerides (β =0.21(0.05–0.38),
P=0.01) and HDL-cholesterol (β =0.31(0.09–0.54), P< 0.01) were
identified in the OPCOS group (Table III). However, after correction
for multiple testing only birthweight, triglycerides and HDL-cholesterol
remained significant.
Analysis with the adjusted model revealed that OPCOS (n=298)
exhibited increased plasma levels of fasting insulin (β =0.21(95%CI:
0.01–0.41), P=0.05), insulin-resistance (β =0.21(95%CI:0.01–0.42),
P=0.04), triglycerides (β =0.19(95%CI:0.02–0.36), P=0.03) and
HDL-cholesterol concentrations (β =0.31(95%CI: 0.08–0.54),
P< 0.01), but reduced birthweight (β =−116(95%CI: −195 to 38),
P< 0.01) compared to controls (n=587). After correcting for multiple
testing, only the differences in HDL-cholesterol and birthweight
remained significant (Table III).
Effect modification by sex in metabolic
profile in offspring of women with or without
PCOS
We also investigated in the adjusted models whether effect modifi-
cation by sex of the child played a role in the association between
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Table II Baseline characteristics of all 885 first visits of offspring of women with PCOS and controls in this IPD analysis.
Sir-Peterman
et al. – Chilean data
Legro
et al. – USA data
De Wilde
et al. – Dutch data
......................................... ......................................... ..........................................
n=288 n=225 n=372
......................................... ......................................... ..........................................
PCOS Controls PCOS Controls PCOS Controls
................... ................... ................... ................... ................... ...................
n=119 n=169 n=105 n=120 n=74 n=298
........................................................................................................................................................................................
Baseline at birth
.........................................................................................................................................................................................
Sex (% girls) 70 (59) 80 (47) 90 (86) 103 (86) 36 (48.6) 171 (57.4)
Gestational age (weeks), median (IQR) 39.0 (38.0–40.0) 39.0 (38.0–40.0) 40.0 (39.0–40.0) 40.0 (40.0–40.0) 39.1 (38.2–40.4) 39.6 (39.0–40.6)
Birthweight (grams), mean (±) 3287± 589 3323± 515 3726± 637 3806± 637 3304± 648 3569± 488
Multiple gestation (%) 0 (0%) 0 (0%) 2 twin pairs (1%) 1 twin pair (2%) 2 twin pairs (5%) 4 twin pairs (3%)
.........................................................................................................................................................................................
Screening during childhood
.........................................................................................................................................................................................
Age at screening (year), mean (±) 9.1± 3.6 10.4± 3.1 9.2± 3.5 10.2± 3.6 4.9± 2.0 5.6± 2.2
BMI (kg/m2), median (IQR) 19.3 (16.7–22.4) 20.1 (17.4–22.8) 19.8 (15.8–22.4) 19.6 (16.1–21.9) 15.6± 1.6 16.1± 1.5
Waist (cm), median (IQR) 62 (56–72) 66 (60–73) 62 (55–74) 66 (56–75) 52 (50–55) 55 (52–58)
Waist to height ratio, mean (±) 0.49± 0.1 0.47± 0.1 0.48± 0.1 0.47± 0.1 0.48± 0.1 0.48± 0.1
SBP (mm Hg), mean (±) 91± 11 93± 13 106± 14 107± 11 98± 8 99± 9
DBP (mm Hg), mean (±) 56± 9 57± 10 65± 8 65± 8 51± 7 52± 6
Fasting glucose (mg/dL), mean (±) 83± 10 83± 9 78± 10 78± 12 84± 6 82± 11
Fasting 2-hour glucose (mg/dL),
mean (±)
99± 24 95± 17 86± 20 82± 17 NA NA
Fasting insulin (μU/ml), median (IQR) 8 (5–14) 10 (6–14) 15 (6–21) 13 (7–15) 4 (2–5) 5 (4–7)
Fasting 2-hour insulin (μU/ml), median
(IQR)
33 (13–63) 32 (18–51) 52 (31–86) 49 (28–67) NA NA
HOMA-IR, median (IQR), median (IQR) 2.3 (1.1–2.8) 2.0 (1.2–2.8) 3.3 (1.2–4.1) 2.5 (1.3–2.0) 0.9 (0.5–1.2) 1.1 (0.7–1.4)
LDL-cholesterol (mg/dL), mean (±) 93± 31 90± 35 58± 25 55± 21 120± 48 106± 24
Total cholesterol (mg/dL), mean (±) 157± 30 167± 31 150± 29 145± 12 189± 51 170± 27
HDL-cholesterol (mg/dL), mean (±) 44± 13 42± 10 84± 53 69± 32 56± 12 56± 10
Triglycerides (mg/dL), mean (±) 114± 45 116± 36 85± 27 82± 30 62± 21 42± 18
Metabolic sum score-1 (SDS), mean (±) 1.5± 2.9 1.0± 2.7 0.5± 4.0 1.6± 2.2 −0.9± 1.2 −1.3± 2.0
Metabolic sum score-2 (SDS), mean (±) 0.2± 2.6 0.1± 2.4 −1.4± 4.3 −0.3± 1.9 −0.9± 1.1 −1.6± 1.8
Tanner stage: pubic hair NA NA 1 (1–2) 1 (1–3) NA NA
Tanner stage: breasts 2 (1–4) 2 (1–4) 1 (1–3) 1 (1–4) NA NA
Tanner stage: testis 2 (1–3) 2 (1–4) 2 (0–4) 1 (0–2) NA NA
Maternal age during screening child
(years), mean (±)
34.6± 7.2 37.9± 6.8 35.6± 5.8 NA 37.0± 4.4 38.2± 4.6
PCOS: polycystic ovary syndrome, SBP/DBP= systolic/diastolic blood pressure, NA=not available data, SDS= standardized deviation score, WHO=World Health Organization.
Baseline characteristics in: n (%), mean (±: SD) or median with interquartile range (IQR): 25–75th percentile.
offspring status (PCOS mother or mother without PCOS) and
cardiometabolic outcome. This was the case for 2 hour post-load
insulin, LDL-cholesterol, total cholesterol, HDL-cholesterol and both
metabolic sum scores (Table IV). However, after correction for
multiple testing, only the interaction test for LDL-cholesterol, total
cholesterol, HDL-cholesterol and metabolic sum score-1 remained
significant. In brief, female OPCOS presented with lower LDL-
cholesterol, lower total cholesterol and lower metabolic sum score-
1 compared to female controls, compared to the mean difference
among males. HDL-cholesterol differences were slightly larger in
.
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.
female OPCOS versus controls, compared to the difference among
males (Table IV).
Discussion
The current systematic review of the literature and subsequent IPD
meta-analysis was designed to assess whether OPCOS present with
less favorable cardiometabolic features compared to offspring of
healthy controls. First, the adjusted IPD analyses of all initial offspring
screenings (n=885) demonstrated that OPCOS (n=298) exhibited
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Table III Cardiometabolic profile parameters recorded at all 885 first visits (229 males, 550 females), analyzed by using
mixed model analysis unstratified for sex of the offspring.
Outcomes PCOS: n=298 Controls:
n=587
Basic model
– Estimated
difference: PCOS
versus controls
(95%CI)
P Adjusted model –
Estimated
difference: PCOS
versus controls
(95%CI)
Adjusted P
..............................................
Mean (±)
.........................................................................................................................................................................................
Anthropometrics
.........................................................................................................................................................................................
Birth weight (g) 3446(653) 3555(554) −129(−208 to −51) <0.01∗∗∗ −116(−195 to −38) <0.01∗∗∗
BMI SDS (WHO
references)
0.84(1.25) 0.64(1.13) 0.03(−0.05 to 0.12) 0.68 0.03(−0.14 to 0.19) 0.74
Waist to height ratio
(WtHR)
0.08(1.21) 0.08(1.01) 0.03(−0.13 to 0.19) 0.70 0.03(−0.13 to 0.18) 0.73
Waist SDS 0.21(3.39) 0.00(1.01) 0.02(−0.14 to 0.18) 0.81 0.01(−0.15 to 0.18) 0.87
SBP SDS −0.15(1.25) −0.16(1.16) 0.12(−0.04 to 0.29) 0.15 0.14(−0.03 to 0.31) 0.11
.........................................................................................................................................................................................
Endocrine markers
.........................................................................................................................................................................................
Fasting glucose SDS −0.03(0.96) −0.04(0.99) 0.04(−0.14 to 0.22) 0.68 0.04(−0.14 to 0.22) 0.68
Fasting insulin∗ SDS 0.39(1.0) −0.03(1.00) 0.21(0.03 to 0.40) 0.03 0.21(0.01 to 0.41) 0.05
HOMA-IR∗ SDS 0.39(1.28) −0.03(1.00) 0.23(0.03 to 0.44) 0.02 0.21(0.01 to 0.42) 0.04
Fasting 2 hour glucose
SDS
−0.69(0.54) −0.68(0.58) −0.03(−0.13 to 0.08) 0.64 −0.02(−0.13 to 0.09) 0.72
Fasting 2 hour insulin∗
SDS
0.29(1.29) 0.02(1.04) 0.27(0.01 to 0.53) 0.04 0.20(−0.09 to 0.49) 0.18
.........................................................................................................................................................................................
Lipid profile
.........................................................................................................................................................................................
LDL-cholesterol SDS −0.26(1.11) −0.04(1.00) −0.07(−0.26 to 0.11) 0.46 −0.09(−0.28 to 0.10) 0.37
Total cholesterol SDS −0.10(1.03) −0.01(0.99) −0.01(−0.21 to 0.20) 0.96 −0.05(−0.25 to 0.15) 0.66
HDL-cholesterol SDS 0.34(1.87) 0.08(1.02) 0.31(0.09 to 0.54) <0.01∗∗∗ 0.31(0.08 to 0.54) <0.01∗∗∗
Triglycerides (TG) SDS 0.35(1.03) −0.08(0.98) 0.21(0.05 to 0.38) 0.01∗∗∗ 0.19(0.02 to 0.36) 0.03
.........................................................................................................................................................................................
Cardiometabolic health
.........................................................................................................................................................................................
Metabolic sum score-1:
BMI+ SBP+ INSULIN+ TG±HDL
0.89(3.27) −0.14(2.65) 0.29(−0.40 to 0.61) 0.38 0.30(−0.36 to 0.95) 0.38
Metabolic sum score-2:
WtHR+ SBP+Glucose+ TG+−HDL
−0.52(3.33) −0.82(2.24) 0.08(−0.52 to 0.68) 0.80 0.18(−0.43 to 0.80) 0.56
∗ = square root of fasting insulin and HOMA-IR, ∗∗ = in the Methods section the rationale was postulated for the models used, ∗∗∗ = P-value remained significant after correction for
multiple testing, Bold text = P-values below 0.05, HOMA-IR= ([fasting insulin (μU/ml)∗fasting glucose (mmol/liter)]/405) (Matthews 1985)], SDS= z-score.
Outcomes are presented in standardized (except for birthweight) mean estimated differences with a 95%CI and P-value: offspring of women with PCOS versus controls. We tested a
basic and an adjusted model, as follows.
Models used∗∗: In the basic model (model 1), birthweight was adjusted for gestational age and country from which the children originated (USA, Chile or The Netherlands). And in the
adjusted model (model 2), we additionally adjusted for sex, parity, multiple gestation and presence of siblings in this study.
In two variables, we calculated SDS using an external reference population: WHO-based BMI SDS and the CDC-based SBP. In the WHO-based BMI SDS, the age and sex of the child
are taken into account in the basic model (model 3) and we additionally adjusted for country from which children originated. In the adjusted model (model 4), we also adjusted for parity,
multiple gestation and presence of siblings in this study. In the CDC-based SBP SDS: sex, height and age were taken into account and we additionally adjusted for country from which
children originated (model 5). In the adjusted model (model 6), we added similar factors as in BMI SDS, with the addition of the offspring weight.
For all other outcomes: in the basic model (model 7), we adjusted for: age of the child and the country from which the children originated (USA, Chile or The Netherlands). In the
adjusted model (model 8), we additionally corrected for sex of the child, parity of the mother, multiple gestation and whether children had any siblings in the IPD included.
In all variables, with exception for birthweight, SDS was used.
P-value <0.017 was considered significant, as we had to correct our analysis for multiple testing (P-value of 0.017 was calculated as: 0.05 divided by 3).
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Table IV Cardiometabolic profile parameters of all 885 first visits stratified for sex of the offspring and assessed by mixed
model analysis.
Outcomes Male PCOS offspring
versus controls: Estimated
difference (95%CI)
Female PCOS offspring
versus controls: Estimate
difference (95%CI)
Interaction term for sex
difference: PCOS versus
controls P-value
.........................................................................................................................................................................................
Anthropometrics
.........................................................................................................................................................................................
Birthweight (grams) −69(−174 to 35) −126(−232 to 21) 0.68
BMI SDS: WHO reference −0.10(−0.37 to 0.18) 0.11(−0.21 to 0.59) 0.45
WtHR SDS 0.03(−0.20 to 0.26) 0.03(−0.18 to 0.24) 0.73
Waist SDS −0.03(−0.28 to 0.21) 0.05(−0.16 to 0.25) 0.71
SBP SDS 0.30(−0.01 to 0.62) 0.04(−0.16 to 0.25) 0.09
.........................................................................................................................................................................................
Endocrine markers
.........................................................................................................................................................................................
Fasting glucose SDS 0.03(−0.20 to 0.27) −0.01(−0.27 to 0.27) 0.98
Fasting insulin SDS 0.11(−0.16 to 0.38) 0.21(−0.08 to 0.49) 0.88
HOMA-IR SDS 0.11(−0.16 to 0.37) 0.22(−0.07 to 0.51) 0.75
Fasting 2 hour glucose SDS −0.03(−0.16 to 0.10) −0.02(−0.18 to 0.13) 0.75
Fasting 2 hour ∗ insulin SDS −0.20(−0.58 to 0.19) 0.45(0.07 to 0.83) 0.03
.........................................................................................................................................................................................
Lipid profile
.........................................................................................................................................................................................
LDL-cholesterol SDS 0.27(−0.03 to 0.57) −0.39(−0.62 to −0.16) <0.01∗∗∗
Total cholesterol SDS 0.28(−0.01 to 0.56) −0.31(−0.57 to −0.06) 0.01∗∗∗
HDL-cholesterol SDS 0.13(−0.05 to 0.31) 0.53(0.18 to 0.88) <0.01∗∗∗
TG SDS 0.12(−0.11 to 0.34) 0.26(0.01 to 0.51) 0.52
.........................................................................................................................................................................................
Cardiometabolic health
.........................................................................................................................................................................................
Metabolic sum score-1
BMI+ SBP+ INSULINE+ TG+HDL
0.85(−0.10 to 1.79) −0.14(−1.05 to 0.77) <0.01∗∗∗
Metabolic sum score-2:
WtHR+SBP+Glucose+ TG+HDL
0.64(−0.17 to 1.45) −0.19(−1.12 to 0.74) 0.02
Outcomes are presented in mean estimated differences with a 95%CI: PCOS offspring versus controls. We tested whether sex of the child was a significant mediator, when comparing
PCOS offspring versus controls.
∗ = square root of insulin, ∗∗∗ = P-value remained significant after correction for multiple testing. Bold text = P-values below 0.05.
Models used: In birthweight, we adjusted for country from which the children originated, gestational age, siblings in the dataset and multiple gestation.
In SBP, we adjusted for: country from which the children originated, gestational age, multiple gestation, siblings in the dataset, age of the child and BMI of the child. In all remaining
parameters, we adjusted for country from which the children originated, gestational age, multiple gestation, siblings in the dataset and age of the child.
P-value < 0.017 was considered significant, as we had to correct our analysis for multiple testing (P-value of 0.017 was calculated as: 0.05 divided by 3). The P-value was the result of the
interaction test for sex; we did not report mean estimated differences for the interaction test. The estimated differences (95%CI) presented in this table for males and females separately
are the differences in male PCOS offspring versus male controls, and female PCOS offspring versus female controls. We refrained from the reporting of P-values for these secondary
analyses.
significantly increased fasting insulin and insulin resistance, HDL-
cholesterol and triglyceride concentrations, but lower birthweight
compared to controls (n=587). However, after correction for
multiple testing, only the mean differences in birthweight and
HDL-cholesterol remained significant. Second, we identified significant
effect modification by sex in 2 hour post-load insulin, LDL-cholesterol,
total cholesterol, HDL-cholesterol and both metabolic sum scores.
After correction for multiple testing, effect modification by sex was
only statistically significant in LDL-cholesterol, total cholesterol, HDL-
cholesterol and metabolic sum score-1. Only in the female offspring
did we observe estimated differences (95%CI) that did not contain the
neutral value; female OPCOS have a higher insulin concentration and
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HDL-cholesterol, but a lower LDL-cholesterol and total cholesterol
compared to female controls.
This study demonstrates that PCOS and its associated features in
the mothers have implications for offspring health, with potential sex-
dependent alterations in metabolic profiles in childhood. These con-
clusions were based on data of individual studies of level IV evidence
(data of case-control studies), which reflects the need for high-validity
studies on the metabolic health of children from mothers with PCOS
(Sackett, 1989).
In the current study, we also investigated whether birthweight dif-
fered between OPCOS and controls. Birthweight is of interest due to
its direct link with cardiovascular disease (CVD) later in life and in adult-
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hood (Ibanez et al., 2011). Conditions of the intra-uterine environment
are partially reflected in birthweight (Barker et al., 1989). The lower
birthweight observed in OPCOS compared to controls is in agreement
with a meta-analysis conducted earlier by our research group involving
both high- and low-quality studies (Boomsma et al., 2006). This effect
could be mediated to some extent by an increased incidence of pre-
eclampsia next to maternal metabolic dysfunction (Boomsma et al.,
2006; Christ et al., 2018). The definition of low birthweight according
toWHO is a birthweight below 2500 g, independent of gestational age.
Only 3.6% of all infants in our study had a low birthweight; 5.1% in the
OPCOS and 2.9% in the controls. This difference was not statistically
significant. Therefore, we do not expect the cardiovascular profiles
to deviate solely because of differences in birthweight, in this study
(WHO, 2012).
BMI, waist-to-height-ratio, waist circumference and blood pressure
in OPCOS were comparable to the measurements in controls, despite
the well-known increased incidence of obesity among adult women
diagnosed with PCOS (Teede et al., 2013). Only one of the included
Chilean studies reported that BMI of OPCOS was significantly higher
compared to the BMI of controls (Recabarren et al., 2008). Waist
circumference in Dutch children participating in the current study was
smaller compared to the American and Chilean offspring, and blood
pressure was systematically higher in Dutch and American compared
to Chilean offspring. Differences in BMI and blood pressure between
studies potentially reflect the influence of intercontinental differences
in the IPD meta-analysis, which were considered in our analyses by
correcting for the continent the offspring originated from. The refer-
ence data we used for BMI from WHO were based on a multi-ethnic
dataset with children from Brazil, Ghana, India, Norway, Oman and
the USA. We believe that since North-America, South-America and
North-Europe were represented in this reference data, generalizability
of the reference data to the IPD meta-analysis study population was
warranted (WHO, 2006, 2011). The CDC data, which were used as
reference data for blood pressure, were retrieved from a multi-ethnic
American population, in which all races were represented (National
Institutes of Health, 2004). Therefore, we also expect reasonable
generalizability of this reference data to our IPD meta-analysis study
population.
After correction for multiple testing, we could not confirm a differ-
ence in insulin resistance in the totalOPCOS population versus the con-
trols. However, the increased 2 hour post-load insulin concentrations
in female OPCOS might have implications later in life. For instance, the
association between insulin concentrations during childhood and later
life onset of type 2 diabetes mellitus has been investigated repeatedly
(Morrison et al., 2011) and gave rise to conflicting results regarding the
age at which such an association could be identified. Nonetheless, a
significant association of increased insulin concentrations during child-
hood and later life type 2 diabetes mellitus, has been demonstrated
regardless of BMI (Nguyen et al., 2010; Morrison et al., 2011; Sabin
et al., 2015).
The higher triglyceride concentrations observed in OPCOS may
seem unfavorable. Nevertheless, increased lipid levels during childhood
do not appear to predict unfavorable lipid profiles in adulthood (Lozano
et al., 2016).We observed lower LDL-cholesterol and total cholesterol
concentrations in female OPCOS in comparison with female controls.
HDL-cholesterol concentrations in female OPCOS seem higher in
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daughters of women with PCOS compared to controls. The higher
HDL-cholesterol in OPCOS might seem contradictory, since HDL-
cholesterol may play a protective role in developing CVD in later life
(Assmann and Gotto, 2004). A Scandinavian study, however, suggests
that the adults with the highest ranges of HDL-cholesterol actually may
have an increased chance for CVD (Madsen et al., 2017). This is a
potential explanation for our finding. But caution is warranted, since
our study does not provide sufficient data to predict lipid profiles of
OPCOS in adulthood. It also should be noted that there may be a sex-
ual dimorphism regarding the expression of both insulin and lipids in the
offspring of women diagnosed with PCOS, with an early appearance
of hyperlipidemia and hyperinsulinemia in girls and a normal insulin
and lipid profile in boys. This sexual dimorphism in both insulin and
lipids has been reported earlier in normal adolescent girls compared
to boys (Barja et al., 2013). Thus, biomarkers in daughters and sons
of women with PCOS seem to be modulated in part by the naturally
occurring biological differences related to sex (Kirchengast and Marosi,
2008; Marceau et al., 2011; Dearden et al., 2018). Sex differences
in physical activity could also influence cardiometabolic outcome in
offspring (Andersen et al., 2006). Supporting for this presumed sexual
dimorphism comes from the higher 2 hour post-load insulin in OPCOS
females compared to male OPCOS (Supplementary Table SIV).
It has been hypothesized that offspring health is determined by an
interplay between genetic and environmental factors (Horwitz and
Neiderhiser, 2011). The Barker hypothesis proposes that early genetic
adaptation to suboptimal conditions in uteromay translate into adverse
health later in life (Baker et al., 2007). The onset of CVD has been
observed in childhood. For instance, a post-mortem study in human
adolescents and young adults who died from external injury, revealed
the existence of manifest atherosclerosis early in life (PDAY Research
Group, 1993). In contrast to these findings, we were unable to observe
an increased metabolic sum score during childhood in OPCOS com-
pared to controls. Our sample size may still be too small to detect
subtle differences. We used a composite outcome: two variants of the
metabolic sum score (arbitrarily defined as the sum of BMI or waist-
to-height ratio, SBP, fasting and post-load insulin or glucose, triglyc-
erides and HDL-cholesterol (metabolic sum score-1), or the sum of
waist-to-height ratio, SBP, glucose, triglycerides, and HDL-cholesterol
(metabolic sum score-2)) to mimic the multifactorial origin of CVD,
as previously described ((Poulter, 1999), personal communication).
Both vascular and metabolic factors contribute to the onset of CVD
((Poulter, 1999), personal communication).
The mechanisms underlying potential differences between OPCOS
and healthy controls are diverse and incompletely understood (Hom-
burg et al., 2017). Maternal overweight induces the transport of glu-
cose, free fatty acids and amino acids to the fetus (Whitaker and Dietz,
1998). Metabolic and adipocyte function could thereby be altered and
influence the development of offspring (de Ferranti and Mozaffarian,
2008). Conflicting theories have been put forward regarding the role
of maternal androgens. It is suggested that hyperandrogenemia of
the mother has a limited influence on the fetus due to the placental
aromatase activity, which converts maternal androgens to estrogens
(Simpson, 2002). However, the changing activities of placental enzymes
diminish the conversion of androgens to estrogens, which could in
theory lead to an increased testosterone supply from the placenta.
This theory was not confirmed in two studies in which cord-blood
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testosterone was measured with liquid chromatography–tandem mass
spectrometry assays (Caanen et al., 2016; Daan et al., 2017). Studies in
women with PCOS revealed macroscopic and microscopic alterations
of the placenta, suggesting a deviant intrauterine environment com-
pared to healthy controls (Maliqueo et al., 2013; Palomba et al., 2013).
A small study of PCOS suggested that amniotic fluid androgen concen-
trations were elevated (Palomba et al., 2012). This was only observed
in women pregnant of a female fetus, again suggesting potential sexual
dimorphism (Palomba et al., 2012). Unfortunately, our data do not
allow the elucidation of any causal mechanism for the alterations in
OPCOS.
Owing to the age criteria applied in this IPD meta-analysis, puberty
does play a role in this study. It is well known that puberty affects serum
markers and, specifically, an early onset of puberty could influence the
cardiometabolic profile (Ibanez et al., 2014). Of the included studies,
we know that the Chilean research group excluded girls with preco-
cious pubarche. Data on puberty of the offspring were recorded in
the American and Chilean offspring only and reported in our baseline
table (Table II). Tanner stages across studies appeared to be quite
similar. Dutch OPCOS were included at 2.5–4 and 6–8 years of age,
therefore, we refrained from recording there pubertal status. We did
not use Tanner stages in our analyses due to the selective reporting
and missing values in the Tanner data in the included studies. Another
reason for this was the inconsistent data on age at menarche in women
with PCOS themselves. A recent large Scandinavian cohort study does
not confirm a lower age at menarche in women with PCOS compared
to controls, as often suggested (Welt and Carmina, 2013; Koivuaho
et al., 2019).
To the best of our knowledge, the current study represents the
first IPD meta-analysis concerning cardiometabolic health in OPCOS.
Rigorous methodology was applied when analyzing the data. Presum-
ably due to the large sample size we were able to detect distinct sex-
differences, while previous individual studies among OPCOS mainly
focused on females, with often limited sample size (Sir-Petermann et al.,
2007, 2009; Kent et al., 2008; Wilde et al., 2018).
Several limitations should also be considered when interpreting our
study results. In the current study, we used international external
reference sources to calculate sex- and age-dependent SDS for BMI
and SBP, which represents both strength and a limitation. The additional
correction for sex by using interaction terms and stratification methods
may have resulted in an underestimation of differences between males
and females. On the other hand, the external reference sources do
increase the external validity to other study populations.
The stratified analyses in male and female offspring suggest that
females are influenced more compared to males by having mothers
with PCOS. It could also be the cases that we did not observe any
differences among males because of a lower number of male offspring
in our dataset.
Another limitation is the limited data obtained on the mode of con-
ception, precluding the assessment of a possible influence of infertility
treatment per se. The Chilean study group reported that only children
who were conceived naturally were eligible for participation in the
follow-up study (Recabarren et al., 2008).
Further details on pregnancies and parental health were not avail-
able. Therefore, we were not able to detect differences in familial or
genetic predisposition for CVD between OPCOS and controls. It is
plausible that a compromised familial history on CVD does encourage
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participation in an offspring follow-up study and introduces a selection
bias.
Last, we must emphasize that we were not able to rule out any
influence of sampling time differences and inter-assay variability on
serum markers. We were not able to analyze one similar sample in
every participating laboratory and with the same assay used in all the
studies. We minimized the effect of different assay use by applying a
mixed effect model, in which we added a random effect for country of
origin of the child.
In conclusion, we observed in the current IPD meta-analysis of
children born from women diagnosed with PCOS subtle signs of a
compromised cardiometabolic health, predominantly in female off-
spring. The unfavorable cardiovascular profile of women with PCOS
at childbearing age may—next to a genetic predisposition—influence
health of their offspring.
It appears crucial to be able to make a distinction between the
effects of a genetic predisposition and suboptimal conditions during
pregnancywhen aiming to improve the future health of OPCOS (Colilla
et al., 2001; Franks, 2002). To achieve this, more high validity follow-
up studies on OPCOS are necessary with clearly defined endpoints on
cardiometabolic health.
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Supplementary data are available atHuman Reproduction Update online.
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